Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Insertion and potential direct-acting antivirals resistance-associated substitutions of DE/−17–0414

From: Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o

Genomic regions Amino acid position Reference amino acid DE/−17–0414 Susceptibility to DAA according to Geno2Pheno[HCV] (Kalaghatgi et al., 2016)
E2 1a-1c QSR NAa
NS3 36 V L Substitution on scored position to Asunaprevir, Grazoprevir, Ledipasvir, Paritaprevir; Reduced susceptibility to Simeprevir, Telaprevir, Voxilaprevir; Resistant to Boceprevir
NS3 170 I V Substitution on scored position to Voxilaprevir
NS5A 28 L M Substitution on scored position to Ombitasvir
NS5A 31 L M Substitution on scored position to Velpatasvir
NS5A 93 Y H Substitution on scored position to Pibrentasvir; Resistant to Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Velpatasvir
  1. aNA for not available